Immunovant, Inc. financial metrics

Professional SEC-based dashboard for profitability, financial health, and growth with transparent scoring logic. Latest period: Q4 2025.

Symbol
IMVT on Nasdaq
Location
Durham, NC
Fiscal year end
31 March
Latest financial report
06 Feb 2026

Quick Takeaways

  • IMVT - Immunovant, Inc. financial facts are built from SEC company filings data.
  • Latest metrics period on this page: Q4 2025.
  • Headline metric: Return On Equity -69%.

What Changed

  • Return On Equity YoY change: <span class="text-red-600">-6.5%</span>.
  • Most recent SEC facts end date: 02 Feb 2026.

Why This Matters

  • This gives a beginner-friendly first read before you inspect detailed formulas and metric tables.
  • Every metric card links to a deeper SEC-backed history page for verification.

Official SEC Source

Based on latest 10-Q/10-K

Facts and ratios are grounded in SEC company facts linked to the latest 10-Q/10-K cycle.

See Original Filing

Latest SEC snapshot (2026-02-02) highlights Return On Equity -69.3%, Return On Assets -41.3%, and Operating Margin 0.0%.

Financial Quality Score

Transparent 0-100 scoring model based on profitability, financial health, and growth factors.

17.6/100

Weak Confidence medium

Return On Equity

-69%

Metric score 0.0/100

Return On Assets

-41%

Metric score 0.0/100

Financial Health

Current Ratio
15.74x
Quick Ratio
15.04x
Debt to Equity
0.09x

Strengths

Debt-to-equity

Watchpoints

Return On Equity, Return On Assets, and Operating Margin

Key metrics snapshot

Return On Equity

-69%

YoY: -6.5%

Industry median: -47% (n=218)

View history

Return On Assets

-41%

YoY: -6.8%

Industry median: -44% (n=217)

View history

Operating Margin

0%

YoY:

Industry median: -263% (n=94)

View history

Current Ratio

15.74x

YoY: +161%

Industry median: 3.67x (n=218)

View history

Quick Ratio

15.04x

YoY: +173%

Industry median: 2.03x (n=83)

View history

Debt-to-equity

0.09x

YoY: -24%

Industry median: 0.31x (n=169)

View history

NetIncomeLoss YoY

-21%

YoY:

Industry median: -12% (n=211)

View history

Profitability

Metric Latest value YoY change
Return On Equity -69% -6.5%
Return On Assets -41% -6.8%
Operating Margin 0%

Financial Health

Metric Latest value YoY change
Current Ratio 15.74x +161%
Quick Ratio 15.04x +173%
Debt-to-equity 0.09x -24%

Growth

Metric Latest value YoY change
NetIncomeLoss YoY -21%

Share Metrics

Metric Latest value YoY change
Entity Common Stock, Shares Outstanding 203,532,180 +20%
Common Stock, Shares, Outstanding 203,316,885 +38%
Common Stock, Value, Issued $20,000 +43%
Weighted Average Number of Shares Outstanding, Basic 181,513,386 +24%
Weighted Average Number of Shares Outstanding, Diluted 181,513,386 +24%

Additional Metrics

Metric Latest value YoY change
General and Administrative Expense $79,149,000 +10%
Income (Loss) from Continuing Operations before Income Taxes, Noncontrolling Interest $460,556,000 -21%
Income Tax Expense (Benefit) $3,643,000 +576%
Earnings Per Share, Basic -2.68 -3.1%
Earnings Per Share, Diluted -2.68 -3.1%
Cash and Cash Equivalents, at Carrying Value $994,525,000 +165%
Accounts Receivable, after Allowance for Credit Loss, Current $1,643,000 -26%
Assets, Current $1,042,939,000 +153%
Property, Plant and Equipment, Net $531,000 -29%
Other Assets, Noncurrent $8,922,000 +17%
Assets $1,052,392,000 +150%
Accounts Payable, Current $8,616,000 -57%
Liabilities, Current $66,257,000 -3%
Liabilities $66,257,000 -3%
Accumulated Other Comprehensive Income (Loss), Net of Tax $1,197,000 -52%
Retained Earnings (Accumulated Deficit) $1,597,273,000 -41%
Stockholders' Equity Attributable to Parent $986,135,000 +180%
Liabilities and Equity $1,052,392,000 +150%
Common Stock, Shares Authorized 500,000,000 0%
Common Stock, Shares, Issued 203,316,885 +38%
Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents $994,525,000 +165%
Comprehensive Income (Loss), Net of Tax, Attributable to Parent $465,481,000 -22%
Preferred Stock, Shares Authorized 10,010,000
Additional Paid in Capital $2,582,191,000 +74%
Share-based Payment Arrangement, Expense $55,800,000 +18%
Preferred Stock, Par or Stated Value Per Share 0.0001 0%

How we score

This score is transparent and deterministic. We weight profitability, financial health, and growth metrics, then renormalize weights when SEC data is missing.

Metric Weight V1 threshold
ROIC205% to 20%
ROE158% to 25%
ROA102% to 10%
Operating Margin55% to 25%
Current Ratio121.0x to 2.0x
Quick Ratio80.8x to 1.5x
Debt to Equity100.3x to 2.0x (lower is better)
Revenue YoY10-10% to +20%
Net Income YoY10-10% to +20%

How Calculated (standard_v1)

Metrics are computed with a market-consensus convention designed for cross-portal comparability.

  • TTM Operating Income / TTM Revenues
  • Current Assets / Current Liabilities (latest instant quarter)
  • (Current Assets - Inventory) / Current Liabilities; fallback: (Cash+Short-Term Investments + Accounts Receivable) / Current Liabilities
  • Total Debt / Stockholders Equity (latest instant quarter; shared unit; freshest series)
  • TTM Net Income / Average Equity (current quarter + same quarter previous year) / 2
  • TTM Net Income / Average Assets (current quarter + same quarter previous year) / 2
  • TTM NOPAT / Average Invested Capital, where NOPAT=Operating Income*(1-tax rate), Invested Capital=Equity+Total Debt-Cash & ST Investments
  • TTM Revenues YoY
  • TTM Net Income YoY